Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Zhang, Yajing; Xu, Yang; Dang, Xiuyong; Zhu, Zeyu; Qian, Wenbin; Liang, Aibin; Han, Weidong

Zhang, Yajing; Xu, Yang; Dang, Xiuyong; Zhu, Zeyu; Qian, Wenbin; Liang, Aibin; Han, Weidong.

Afiliação

Zhang Y; Department of Bio-Therapeutics, The First Medical Centre, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.
Xu Y; Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
Dang X; Department of Hematology, Tongji Hospital of Tongji University, Shanghai 200065, China.
Zhu Z; Department of Hematology, Tongji Hospital of Tongji University, Shanghai 200065, China.
Qian W; Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
Liang A; Department of Hematology, Tongji Hospital of Tongji University, Shanghai 200065, China.
Han W; Department of Bio-Therapeutics, The First Medical Centre, The General Hospital of Chinese People's Liberation Army, Beijing 100853, China.

Chin Med J (Engl) ; 136(3): 269-279, 2023 Feb 05.

Article em En | MEDLINE | ID: mdl-36848181

Assuntos

Neoplasias Hematológicas; Receptores de Antígenos Quiméricos; Humanos; Receptores de Antígenos Quiméricos/uso terapêutico; Imunoterapia Adotiva; Neoplasias Hematológicas/terapia; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hematológicas / Receptores de Antígenos Quiméricos Limite: Humans Idioma: En Revista: Chin Med J (Engl) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google